KLP Kapitalforvaltning AS trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 70.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,422 shares of the medical equipment provider's stock after selling 194,500 shares during the period. KLP Kapitalforvaltning AS's holdings in Hologic were worth $5,371,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Farther Finance Advisors LLC raised its position in shares of Hologic by 22.3% in the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock valued at $113,000 after buying an additional 335 shares in the last quarter. United Services Automobile Association acquired a new stake in shares of Hologic in the first quarter valued at approximately $347,000. SG Americas Securities LLC raised its position in shares of Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock valued at $594,000 after buying an additional 5,172 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Hologic in the first quarter valued at approximately $641,000. Finally, Cambridge Investment Research Advisors Inc. raised its position in shares of Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock valued at $1,980,000 after buying an additional 528 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.
Hologic Stock Performance
NASDAQ HOLX opened at $67.76 on Friday. The firm's fifty day moving average price is $67.15 and its two-hundred day moving average price is $63.31. The stock has a market cap of $15.07 billion, a PE ratio of 28.12, a PEG ratio of 2.35 and a beta of 0.63. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.
Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.
Insider Buying and Selling at Hologic
In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.88% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on HOLX shares. Mizuho set a $75.00 price objective on shares of Hologic in a research note on Thursday, July 31st. Weiss Ratings reissued a "hold (c-)" rating on shares of Hologic in a research note on Wednesday. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Wednesday, October 1st. Stephens reissued an "overweight" rating and issued a $78.00 price objective on shares of Hologic in a research note on Thursday, September 18th. Finally, Argus lifted their price objective on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research note on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Hologic has an average rating of "Moderate Buy" and an average target price of $80.15.
Read Our Latest Research Report on HOLX
About Hologic
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Further Reading
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
